Luckily I was around at that time, didn't hold out for $29.50 but got close (my average in was also much higher than this go around as well, still a very nice return though). The rumour I heard was Don had a $30 offer sitting on his desk but was holding out for more. The timing of this coincided with Pfizer failing and pulling the pin on torcetrapibInteresting and given Jan Johansson's prior involvement with the sale of the original Esperion to Pfizer everything just fed the rumour. Funny how at that time I thought that a $1 billion market cap, roughly, for a preclinical compound was ridiculously high and now I think the market cap for RVX is just as ridiculously low.